Down-regulation of a novel form of fibroblast growth factor receptor I in human breast cancer
1997

FGFR-1 Variants in Human Breast Cancer

Sample size: 22 publication Evidence: moderate

Author Information

Author(s): C Yiangou, H Cox, GS Bansal, R Coope, JJ Gomm, R Barnard, J Walters, N Groome, S Shousha, RC Coombes, CL Johnston

Primary Institution: Charing Cross and Westminster Medical School

Hypothesis

The study investigates the expression of different forms of fibroblast growth factor receptor 1 (FGFR-1) in normal and cancerous breast tissues.

Conclusion

The 106-kDa form of FGFR-1 is lost in malignant breast cancer cells, which may contribute to malignancy.

Supporting Evidence

  • The 115-kDa beta form of FGFR-1 is predominantly expressed in both benign and malignant epithelial cells.
  • The 106-kDa form of FGFR-1 is expressed in normal breast fibroblasts and myoepithelial cells but lost in malignant epithelial cells.
  • FGFR-1 mRNA was detected in all breast cell populations, indicating its expression in fibroblasts.
  • Immunohistochemistry confirmed the presence of FGFR-1 in normal and malignant breast tissues.

Takeaway

This study found that a specific form of a protein called FGFR-1 is missing in breast cancer cells, which might help explain why these cells grow uncontrollably.

Methodology

The study used Western blot analysis, RT-PCR, and immunohistochemistry to assess FGFR-1 expression in various breast cell lines and tissues.

Limitations

The study may not account for all possible mechanisms affecting FGFR-1 expression in breast cancer.

Participant Demographics

The study included samples from both malignant and non-malignant breast tissues.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication